Pharma Focus Europe

Odyssey Therapeutics Announces Partnership to Drive AI-Powered Small Molecule Drug Discovery

Friday, April 05, 2024

Odyssey Therapeutics, Inc., a pioneering biotechnology company specializing in next-generation precision medicines, announced a significant research collaboration with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson. This collaboration aims to jointly identify and enhance small molecule medicines targeting specific therapeutic areas. Leveraging their expertise in artificial intelligence (AI), machine learning (ML), computational chemistry, and drug discovery, both companies aspire to tackle challenging-to-address medical targets. The agreement, facilitated by Johnson & Johnson Innovation, underscores a strategic alignment towards innovative drug discovery methodologies.

Established in 2021, Odyssey has curated a team of proficient drug hunters proficient in immunology, oncology, medicinal chemistry, and structural biophysics. Empowered by state-of-the-art computational tools, the company is dedicated to resolving complex therapeutic hurdles. By seamlessly integrating in silico methods with cutting-edge experimental capabilities and laboratory infrastructure, Odyssey's scientists can expedite the discovery and development of potentially groundbreaking medicines for patient benefit.

Gary D. Glick, Ph.D., founder and CEO of Odyssey Therapeutics, expressed enthusiasm about the collaboration, highlighting its potential to revolutionize drug discovery processes using AI and ML advancements. Glick emphasized the synergy between chemists, biologists, and data scientists, foreseeing accelerated drug discovery outcomes through enhanced tools, shared data, and model refinement, ultimately aiming to deliver transformative therapies to patients in need.

Per the agreement's terms, Odyssey will collaborate closely with Johnson & Johnson's experts in discovery, therapeutic areas, and data science to harness AI and ML in the pursuit of small molecule therapeutics against various targets. In return, Odyssey will receive an upfront payment, along with potential milestone payments and royalties.

 

Source: businesswire.com

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva